Intravitreal bevacizumab for retinal capillary haemangioma: longterm results.
Ach
Thomas
T
Thiemeyer
Dorothea
D
Hoeh
Alexandra Eva
AE
Schaal
Karen Beate
KB
Dithmar
Stefan
S
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D005500:Follow-Up Studies; D018324:Hemangioma, Capillary / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007267:Injections; D019572:Retinal Neoplasms / Q000188:drug therapy* / Q000209:etiology; D019233:Retreatment; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity / Q000502:physiology; D014822:Vitreous Body; D006623:von Hippel-Lindau Disease / Q000150:complications / Q000188:drug therapy
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab